肿瘤伴随诊断市场－全球产业规模、份额、趋势、机会及预测（按产品/服务、技术、疾病类型、最终用途、地区和竞争格局划分，2021-2031年）

全球肿瘤伴随诊断市场预计将从 2025 年的 32.1 亿美元成长到 2031 年的 50.7 亿美元，复合年增长率为 7.92%。

这些诊断技术是至关重要的医疗设备，旨在确定患者合格接受特定治疗，或识别有发生严重不良反应风险的个体。该领域的发展主要得益于全球向个人化医疗的转变以及需要标靶治疗的癌症发生率不断上升。监管趋势也支持对生物标记指导治疗的日益依赖。根据个人化医疗联盟预测，2024年将有18种新型个人化药物获得FDA核准，约占新核准治疗性分子实体总数的38%。

儘管存在这些积极因素，但该行业在报销结构方面仍面临许多挑战。一个关键障碍是诊断编码系统与支付方的承保政策不匹配，这给产品开发商带来了财务上的不确定性。不同医疗体系间报销决策的不一致，不仅使商业化进程复杂化，也限制了病人获得必要检测服务的机会。这些经济障碍不仅延缓了创新诊断技术的整合，也限制了新兴肿瘤生物标记的潜在市场，最终阻碍了整个产业的成长。

市场驱动因素

全球癌症负担日益加重，凸显了广泛应用伴随诊断以优化治疗策略、减少无效处方的必要性。随着恶性肿瘤发生率的上升，医疗系统越来越需要进行基因组检测，以确保昂贵的治疗方法仅提供给具有特定基因谱且疗效显着的患者。病例数的成长推动了这一需求，成为市场成长的主要动力，迫使实验室扩大检测能力。根据美国癌症协会于2024年1月发布的《2024年癌症事实与数据》报告，预计仅在美国就将新增超过200万例癌症病例，这凸显了诊断分层工具对于应对这一快速增长的患者群体的紧迫性。

同时，精准肿瘤学的快速普及正在改变临床工作流程，并推动标靶治疗的兴起。製药公司正将重心从广谱细胞毒性药物转向生物标记驱动的药物，从而在临床试验招募和商业性化应用方面都对诊断检测产生了相互依赖的影响。这种策略调整使得诊断技术通常与治疗药物共同开发，将不断扩大的诊断市场与药物研发管线直接连结。例如，Astra Zeneca在2024年2月发布的「2023财年全年业绩」公告中确认，其临床研发管线中90%为标靶治疗，这显示整个产业正专注于生物标记依赖性机制。这一趋势正在推动检测数量的显着增长。 Guardant Health报告称，2024年临床检测量较上年增长21%，证实了肿瘤诊断解决方案的应用范围正在扩大。

市场挑战

诊断编码框架与支付方覆盖政策之间的不匹配构成了重大的财务障碍，直接限制全球肿瘤伴随诊断市场的成长。由于报销系统难以跟上快速创新的步伐，开发商面临收入的不确定性，因此不愿投资检验新型生物标记。这种经济上的错配使得即使是经过临床检验的诊断方法也缺乏明确的支付途径，迫使临床检查室在承担相关成本和拒绝为合格的患者提供检测之间做出选择。这削弱了这些重要工具的商业性永续性，限制了它们在常规临床实践中的应用，并阻碍了向个人化医疗的广泛转变。

这种经济负担对市场渗透率产生了显着影响，因为它阻碍了临床实践。根据国际肺癌研究协会 (IASLC) 2024 年全球生物标记检测调查，27.2% 的受访者认为成本是实施必要检测的主要障碍。这些经济挑战有效地限制了潜在市场规模，阻碍了技术的广泛应用。由于医疗服务提供者需要应对不一致的报销规定，患者获得标靶治疗的机会被延迟，最终限制了精准肿瘤学领域的整​​体发展潜力。

市场趋势

市场正经历着从重复的单一生物标记检测到多重次世代定序panel的结构性转变。这项转变的驱动力在于，需要在保留有限切片检查组织的同时，提取尽可能多的基因组讯息，以用于复杂的标靶治疗。与传统的顺序基因检测相比，多重panel能够同时分析数百种基因突变，从而缩短诊断週期，并解决组织耗竭带来的挑战。这种产业整合也体现在检查室的性能指标。根据NeoGenomics于2025年2月发布的“2024年第四季度及全年收益报告”，该公司确认，2024年次世代定序检测量增长了34%，表明行业正迅速向全面的基因组分析转型。

同时，人工智慧 (AI) 和机器学习的融合正在改变诊断的准确性。随着生物数据集呈指数级增长，计算演算法对于解读多组体学数据以及将基因组学发现与临床结果关联至关重要。这种技术融合有助于识别新的生物标记物，从而实现超越传统病理学能力的患者分层。随着越来越多的合作伙伴积极寻求数据驱动的洞察，这些演算法解决方案的商业性势头正在增强。例如，Tempus AI 在 2025 年 2 月发布的「2024 年第四季及全年」财务报告中指出，其数据服务部门的收入同比增长 44.6%，该部门利用了其人工智慧平台，这凸显了计算诊断价值的快速增长。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球癌症伴随诊断市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品/服务分类（产品（设备、耗材、软体）、服务）
  • 依技术（聚合酵素链锁反应（PCR）、次世代定序（NGS）、免疫组织化学（IHC）、原位杂合反应（ISH）/萤光杂合反应（FISH）、其他）
  • 依疾病分类（乳癌、非小细胞肺癌、结肠癌、白血病、黑色素瘤、摄护腺癌、其他）
  • 透过申请（医院、病理/诊断检查室、大学附设医院）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美癌症伴随诊断市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲癌症伴随诊断市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区癌症伴随诊断市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲癌症伴随诊断市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章 南美洲癌症伴随诊断市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球肿瘤伴随诊断市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Agilent Technologies Inc
• Illumina Inc
• QIAGEN NV
• Thermo Fisher Scientific Inc
• F Hoffmann-La Roche AG
• ARUP Laboratories Inc
• Abbott Laboratories Inc
• Myriad Genetics Inc
• bioMerieux SA
• Invivoscribe Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Oncology Companion Diagnostic Market is projected to expand from USD 3.21 Billion in 2025 to USD 5.07 Billion by 2031, registering a compound annual growth rate of 7.92%. These diagnostics act as critical medical devices designed to determine patient eligibility for specific treatments or to identify individuals at risk of severe adverse reactions. The sector's growth is primarily fueled by the global shift toward personalized healthcare and the rising incidence of cancer necessitating targeted interventions. This increasing dependence on biomarker-guided therapy is supported by regulatory trends; according to the Personalized Medicine Coalition, 18 new personalized medicines were approved by the FDA in 2024, accounting for roughly 38 percent of all newly authorized therapeutic molecular entities.

Despite these positive catalysts, the industry faces substantial hurdles related to reimbursement structures. A major obstacle involves the misalignment between diagnostic coding systems and payer coverage policies, which generates financial instability for product developers. Such inconsistent reimbursement decisions across various healthcare systems create complexities in commercialization and restrict patient access to essential testing services. These economic barriers not only delay the integration of innovative diagnostic technologies but also constrain the potential market for emerging oncology biomarkers, thereby hindering the sector's overall growth trajectory.

Market Driver

The increasing global burden of cancer underscores the necessity for widespread companion diagnostic implementation to refine treatment strategies and minimize ineffective prescriptions. As malignancy rates climb, healthcare systems are progressively requiring genomic testing to ensure that expensive therapies are delivered exclusively to patients possessing the specific genetic profiles required for efficacy. This demand, driven by case volume, acts as a primary engine for market growth, compelling laboratories to expand their testing capacities. According to the American Cancer Society's 'Cancer Facts & Figures 2024' report released in January 2024, projections indicate that over 2 million new cancer cases will be diagnosed within the United States alone, highlighting the urgent requirement for diagnostic stratification tools to address this escalating patient load.

Simultaneously, the rapid adoption of precision oncology is transforming clinical workflows and stimulating the increase of targeted therapies. Pharmaceutical companies are pivoting away from broad-spectrum cytotoxic agents toward biomarker-driven medications, establishing a mutual dependency on diagnostic assays for both clinical trial recruitment and commercial delivery. This strategic realignment ensures that diagnostics are often co-developed with therapeutics, linking diagnostic market expansion directly to pharmaceutical pipelines. For instance, AstraZeneca confirmed in its 'Full Year 2023 Results' announcement in February 2024 that 90 percent of its clinical pipeline consists of targeted therapies, demonstrating the industry's focus on biomarker-dependent mechanisms. This trend is resulting in measurable volume increases; Guardant Health reported a 21 percent year-over-year rise in clinical test volume in 2024, confirming the growing application of oncology diagnostic solutions.

Market Challenge

The discrepancy between diagnostic coding frameworks and payer coverage policies represents a significant financial impediment that directly curbs the growth of the global oncology companion diagnostic market. As reimbursement systems struggle to match the pace of rapid technological innovation, developers encounter considerable revenue unpredictability, which deters investment in the validation of new biomarkers. This economic misalignment results in situations where even clinically validated diagnostics frequently lack defined payment channels, compelling clinical laboratories to either absorb the associated costs or refuse testing for eligible patients. As a result, the commercial sustainability of these critical tools is undermined, restricting their availability in routine clinical practice and impeding the wider shift toward personalized medicine.

This financial strain significantly affects market uptake by establishing barriers at the point of care. According to the International Association for the Study of Lung Cancer (IASLC) in its 2024 Global Survey on Biomarker Testing, 27.2 percent of respondents highlighted cost as a major hindrance to implementing essential testing. Such economic challenges effectively limit the total addressable market by precluding widespread adoption. As healthcare providers navigate inconsistent reimbursement rulings, patient access to targeted therapies is postponed, which subsequently suppresses the overall expansion potential of the precision oncology sector.

Market Trends

The market is experiencing a structural transition from iterative single-biomarker assays to multiplex Next-Generation Sequencing panels. This evolution is propelled by the necessity to preserve limited biopsy tissue while extracting maximum genomic information for complex targeted therapies. In contrast to traditional methods that examine genes sequentially, multiplex panels facilitate the simultaneous analysis of hundreds of genetic alterations, thereby shortening diagnostic turnaround times and addressing issues related to tissue exhaustion. This industry consolidation is reflected in laboratory performance metrics; according to the 'Fourth Quarter and Full Year 2024 Results' report by NeoGenomics in February 2025, the company observed a 34 percent growth in its Next-Generation Sequencing test volume during 2024, demonstrating the rapid industrial shift toward comprehensive genomic profiling.

Concurrently, the incorporation of Artificial Intelligence and Machine Learning is transforming diagnostic precision. As biological datasets grow exponentially more complex, computational algorithms have become indispensable for interpreting multi-omics data and linking genomic discoveries with clinical results. This technological convergence aids in the identification of novel biomarkers and enhances patient stratification beyond the capabilities of standard pathology. The commercial momentum of these algorithmic solutions is increasing as partners actively seek data-driven insights. For example, Tempus AI reported in its 'Fourth Quarter and Full Year 2024 Results' announcement in February 2025 that revenue from its Data and Services segment, which leverages AI-enabled platforms, rose by 44.6 percent compared to the prior year, highlighting the escalating value of computational diagnostics.

Key Market Players

• Agilent Technologies Inc
• Illumina Inc
• QIAGEN NV
• Thermo Fisher Scientific Inc
• F Hoffmann-La Roche AG
• ARUP Laboratories Inc
• Abbott Laboratories Inc
• Myriad Genetics Inc
• bioMerieux SA
• Invivoscribe Inc

Report Scope

In this report, the Global Oncology Companion Diagnostic Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Oncology Companion Diagnostic Market, By Product & Service

• Product (Instrument, Consumables, Software)
• Service

Oncology Companion Diagnostic Market, By Technology

• Polymerase chain reaction (PCR)
• Next-generation sequencing (NGS)
• Immunohistochemistry (IHC)
• In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
• Others

Oncology Companion Diagnostic Market, By Disease Type

• Breast cancer
• Non-small cell lung cancer
• Colorectal cancer
• Leukemia
• Melanoma
• Prostate cancer
• Others

Oncology Companion Diagnostic Market, By End Use

• Hospitals
• Pathology/Diagnostic laboratory
• Academic medical center

Oncology Companion Diagnostic Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Oncology Companion Diagnostic Market.

Available Customizations:

Global Oncology Companion Diagnostic Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Oncology Companion Diagnostic Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product & Service (Product (Instrument, Consumables, Software), Service)
  • 5.2.2. By Technology (Polymerase chain reaction (PCR), Next-generation sequencing (NGS), Immunohistochemistry (IHC), In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH), Others)
  • 5.2.3. By Disease Type (Breast cancer, Non-small cell lung cancer, Colorectal cancer, Leukemia, Melanoma, Prostate cancer, Others)
  • 5.2.4. By End Use (Hospitals, Pathology/Diagnostic laboratory, Academic medical center)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Oncology Companion Diagnostic Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product & Service
  • 6.2.2. By Technology
  • 6.2.3. By Disease Type
  • 6.2.4. By End Use
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Oncology Companion Diagnostic Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product & Service
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Disease Type
      • 6.3.1.2.4. By End Use
  • 6.3.2. Canada Oncology Companion Diagnostic Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product & Service
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Disease Type
      • 6.3.2.2.4. By End Use
  • 6.3.3. Mexico Oncology Companion Diagnostic Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product & Service
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Disease Type
      • 6.3.3.2.4. By End Use

7. Europe Oncology Companion Diagnostic Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product & Service
  • 7.2.2. By Technology
  • 7.2.3. By Disease Type
  • 7.2.4. By End Use
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Oncology Companion Diagnostic Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product & Service
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Disease Type
      • 7.3.1.2.4. By End Use
  • 7.3.2. France Oncology Companion Diagnostic Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product & Service
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Disease Type
      • 7.3.2.2.4. By End Use
  • 7.3.3. United Kingdom Oncology Companion Diagnostic Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product & Service
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Disease Type
      • 7.3.3.2.4. By End Use
  • 7.3.4. Italy Oncology Companion Diagnostic Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product & Service
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Disease Type
      • 7.3.4.2.4. By End Use
  • 7.3.5. Spain Oncology Companion Diagnostic Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product & Service
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Disease Type
      • 7.3.5.2.4. By End Use

8. Asia Pacific Oncology Companion Diagnostic Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product & Service
  • 8.2.2. By Technology
  • 8.2.3. By Disease Type
  • 8.2.4. By End Use
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Oncology Companion Diagnostic Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product & Service
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Disease Type
      • 8.3.1.2.4. By End Use
  • 8.3.2. India Oncology Companion Diagnostic Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product & Service
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Disease Type
      • 8.3.2.2.4. By End Use
  • 8.3.3. Japan Oncology Companion Diagnostic Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product & Service
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Disease Type
      • 8.3.3.2.4. By End Use
  • 8.3.4. South Korea Oncology Companion Diagnostic Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product & Service
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Disease Type
      • 8.3.4.2.4. By End Use
  • 8.3.5. Australia Oncology Companion Diagnostic Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product & Service
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Disease Type
      • 8.3.5.2.4. By End Use

9. Middle East & Africa Oncology Companion Diagnostic Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product & Service
  • 9.2.2. By Technology
  • 9.2.3. By Disease Type
  • 9.2.4. By End Use
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Oncology Companion Diagnostic Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product & Service
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Disease Type
      • 9.3.1.2.4. By End Use
  • 9.3.2. UAE Oncology Companion Diagnostic Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product & Service
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Disease Type
      • 9.3.2.2.4. By End Use
  • 9.3.3. South Africa Oncology Companion Diagnostic Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product & Service
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Disease Type
      • 9.3.3.2.4. By End Use

10. South America Oncology Companion Diagnostic Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product & Service
  • 10.2.2. By Technology
  • 10.2.3. By Disease Type
  • 10.2.4. By End Use
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Oncology Companion Diagnostic Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product & Service
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Disease Type
      • 10.3.1.2.4. By End Use
  • 10.3.2. Colombia Oncology Companion Diagnostic Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product & Service
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Disease Type
      • 10.3.2.2.4. By End Use
  • 10.3.3. Argentina Oncology Companion Diagnostic Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product & Service
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Disease Type
      • 10.3.3.2.4. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Oncology Companion Diagnostic Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Agilent Technologies Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Illumina Inc
• 15.3. QIAGEN NV
• 15.4. Thermo Fisher Scientific Inc
• 15.5. F Hoffmann-La Roche AG
• 15.6. ARUP Laboratories Inc
• 15.7. Abbott Laboratories Inc
• 15.8. Myriad Genetics Inc
• 15.9. bioMerieux SA
• 15.10. Invivoscribe Inc

16. Strategic Recommendations

17. About Us & Disclaimer